Hengrui Pharma announced that the FDA has accepted its biologics license application (BLA) for its PD-1 inhibitor camrelizumab in combination with oral VEGFR inhibitor rivoceranib. Hangzhou and New Jersey-based cancer biotechnology company Adlai Nortye filed with the U.S. Securities and Exchange Commission (SEC) to raise up to $115 million in an IPO.